Craig Johnstone - Evotec SE COO Board
| EVO Stock | USD 4.07 0.01 0.25% |
Insider
Craig Johnstone is COO Board of Evotec SE ADR
| Age | 54 |
| Phone | 49 40 560 81 0 |
| Web | https://www.evotec.com |
Evotec SE Management Efficiency
Evotec SE's management efficiency ratios could be used to measure how well Evotec SE manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Muthusamy RPh | ANI Pharmaceuticals | 56 | |
| Erez MBA | Dr Reddys Laboratories | 56 | |
| Daryl Gaugler | Pacira Pharmaceuticals | 62 | |
| Scott Sudduth | Collegium Pharmaceutical | N/A | |
| Mukesh Rathi | Dr Reddys Laboratories | 45 | |
| Jeffrey Zerillo | Prestige Brand Holdings | 63 | |
| Tami Martin | Supernus Pharmaceuticals | 69 | |
| K Krishnan | Dr Reddys Laboratories | 61 | |
| Brian Cahill | Eagle Pharmaceuticals | 55 | |
| MBA MBA | Dr Reddys Laboratories | 55 | |
| Alex Dasalla | Collegium Pharmaceutical | N/A | |
| RPh Pharm | Collegium Pharmaceutical | 60 | |
| Damian Finio | Phibro Animal Health | 54 | |
| Frank Mottola | Supernus Pharmaceuticals | 52 | |
| Eiry MD | Neurocrine Biosciences | 59 | |
| Michelle Chan | Regencell Bioscience Holdings | N/A | |
| Jean Filippi | Phibro Animal Health | N/A | |
| John Kimmet | Eagle Pharmaceuticals | N/A | |
| P Yugandhar | Dr Reddys Laboratories | 49 | |
| Gregory Gentile | Silver Spike Investment | 48 | |
| Adel Mekhail | Prestige Brand Holdings | 63 | |
Management Performance
| Return On Equity | -0.0791 | ||||
| Return On Asset | 3.0E-4 |
Evotec SE ADR Leadership Team
Elected by the shareholders, the Evotec SE's board of directors comprises two types of representatives: Evotec SE inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Evotec. The board's role is to monitor Evotec SE's management team and ensure that shareholders' interests are well served. Evotec SE's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Evotec SE's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Matthias Evers, Chief Board | ||
| Mario DPHIL, Member CEO | ||
| Monika Conradt, Global Resources | ||
| MBA MPA, Member Board | ||
| Christian Dargel, EVP Compliance | ||
| Anja Bosler, Principal Accounting | ||
| Volker Braun, Executive ESG | ||
| Cord Dohrmann, Chief Board | ||
| Enno Spillner, CFO Board | ||
| MBA MBA, Chairman CEO | ||
| Gabriele Hansen, Senior Marketing | ||
| Craig Johnstone, COO Board | ||
| Laetitia Rouxel, CFO Board |
Evotec Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Evotec SE a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0791 | ||||
| Return On Asset | 3.0E-4 | ||||
| Profit Margin | (0.12) % | ||||
| Operating Margin | (0.09) % | ||||
| Current Valuation | 923.78 M | ||||
| Shares Outstanding | 354.37 M | ||||
| Shares Owned By Institutions | 1.41 % | ||||
| Number Of Shares Shorted | 158.26 K | ||||
| Price To Earning | 444.00 X | ||||
| Price To Book | 2.12 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectAdditional Information and Resources on Investing in Evotec Stock
When determining whether Evotec SE ADR offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Evotec SE's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Evotec Se Adr Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Evotec Se Adr Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evotec SE ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evotec SE. If investors know Evotec will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evotec SE listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Evotec SE ADR is measured differently than its book value, which is the value of Evotec that is recorded on the company's balance sheet. Investors also form their own opinion of Evotec SE's value that differs from its market value or its book value, called intrinsic value, which is Evotec SE's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evotec SE's market value can be influenced by many factors that don't directly affect Evotec SE's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evotec SE's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evotec SE is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evotec SE's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.